Australian Pharmaceuticals & Biotech Most Popular Stocks

CSL

Market Cap: AU$122.0b

Researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally.

Telix Pharmaceuticals

Market Cap: AU$8.8b

A commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States.

Mesoblast

Market Cap: AU$2.5b

Engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland.

Neuren Pharmaceuticals

Market Cap: AU$1.4b

A biopharmaceutical company, develops drugs for the treatment of neurological disorders.

Clarity Pharmaceuticals

Market Cap: AU$867.3m

A clinical stage radiopharmaceutical company, engages in research and development and clinical stage radiopharmaceuticals products in Australia and the United States.

Opthea

Market Cap: AU$800.3m

A clinical-stage biopharmaceutical company, develops and commercializes drugs for eye diseases in Australia and the United States.

Botanix Pharmaceuticals

Market Cap: AU$748.5m

Engages in the research and development of dermatology and antimicrobial products in Australia and the United States.

Mayne Pharma Group

Market Cap: AU$587.4m

A specialty pharmaceutical company, manufactures and sells branded and generic pharmaceutical products in Australia, New Zealand, the United States, Canada, Europe, Asia, and internationally.

PYC Therapeutics

Market Cap: AU$564.6m

A drug-development company, engages in the discovery and development of novel RNA therapeutics for the treatment of genetic diseases in Australia.

Clinuvel Pharmaceuticals

Market Cap: AU$562.9m

A biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally.

Immutep

Market Cap: AU$400.3m

A late-stage biotechnology company, engages in developing novel LAG-3 related immunotherapies for cancer and autoimmune diseases in Australia.

Orthocell

Market Cap: AU$290.3m

A regenerative medicine company, develops and commercializes cell therapies and biological medical devices for the repair of various bone and soft tissue injuries in Australia, the United States, the United Kingdom, and the European Union.

Imugene

Market Cap: AU$253.6m

A clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumours in Australia.

Dimerix

Market Cap: AU$220.6m

A biopharmaceutical company, develops and commercializes pharmaceutical products for unmet medical needs in Australia.

Race Oncology

Market Cap: AU$183.3m

A clinical stage biopharmaceutical company, focuses on addressing the unmet needs of cancer patients for damaging treatments.

Paradigm Biopharmaceuticals

Market Cap: AU$175.2m

Engages in the research and development of therapeutic products for human use in Australia.

Aroa Biosurgery

Market Cap: AU$163.8m

Develops, manufactures, and sells medical devices for wound and soft tissue repair using extracellular matrix (ECM) technology in the United States and internationally.

Trajan Group Holdings

Market Cap: AU$123.4m

Develops, manufactures, sells, and distributes analytical and life science products and devices in Australia, New Zealand, Malaysia, Japan, the United States, Europe, the Middle East, Africa, and India.

Genetic Signatures

Market Cap: AU$117.0m

Operates as a molecular diagnostic company in Australia, the Asia Pacific, Europe, the Middle East, Asia, and the Americas.

Syntara

Market Cap: AU$115.3m

Operates as a clinical-stage drug development company that focuses on blood-related cancers in Australia.

Vita Life Sciences

Market Cap: AU$102.9m

A healthcare company, engages in formulating, packaging, distributing, and selling vitamins and supplements in Australia, Singapore, Malaysia, Thailand, Vietnam, Indonesia, and China.

Arovella Therapeutics

Market Cap: AU$100.0m

A biotechnology company, focuses on the development of therapies for the treatment of cancer in Australia and internationally.

LTR Pharma

Market Cap: AU$95.0m

A biopharmaceutical company, engages in the research and development of intranasal spray for the treatment erectile dysfunction (ED) in Australia.

Argenica Therapeutics

Market Cap: AU$94.1m

A biotechnology company, engages in the research and development of neuroprotective therapeutic drug in Australia.

Actinogen Medical

Market Cap: AU$90.9m

A biotechnology company, develops therapies for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol in Australia.

Vitrafy Life Sciences

Market Cap: AU$86.8m

Provides cryopreservation solutions in Australia.

Beroni Group

Market Cap: AU$75.9m

Develops and sells smoking control products, air purifiers, water filters, cosmetics, stem-cell therapies, and health care products and supplements in Australia and internationally.

EZZ Life Science Holdings

Market Cap: AU$75.0m

Engages in formulation, production, marketing, and sale of the health and wellbeing products in Australia, New Zealand, Mainland China, and internationally.

Recce Pharmaceuticals

Market Cap: AU$74.2m

Recce Pharmaceuticals Ltd, discovers, develops, and commercializes synthetic anti–infectives in Australia, the United Kingdom, and the United States.

Radiopharm Theranostics

Market Cap: AU$72.4m

Engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical needs.

Medical Developments International

Market Cap: AU$66.5m

Manufactures and distributes emergency medical solutions in Australia, Europe, the United States, and internationally.

Proteomics International Laboratories

Market Cap: AU$62.9m

Operates as a medical technology company with a focus on the area of proteomics in Australia, New Zealand, the United States, Europe, India, and South East Asia.

Neurizon Therapeutics

Market Cap: AU$56.6m

A clinical stage biotechnology company, develops therapeutics for neurodegenerative diseases in Switzerland, Australia, the United States, and internationally.

Alterity Therapeutics

Market Cap: AU$54.9m

Engages in the research and development of therapeutic drugs to treat Alzheimer’s disease, Huntington disease, Parkinson’s disease, and other neurological disorders in Australia.

Cynata Therapeutics

Market Cap: AU$47.3m

Engages in the development and commercialization of proprietary induced pluripotent stem cell and mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia.

Vitura Health

Market Cap: AU$46.4m

Engages in the sale and distribution of medicinal cannabis products in Australia.